SSTR2: The Potential Drug Target and Biomarker for Stroke (G6752)

Target Name: SSTR2

NCBI ID: G6752

SSTR2

SSTR2: The Potential Drug Target and Biomarker for Stroke

Stroke is a leading cause of death worldwide, affecting millions of people each year. Despite advances in treatment, the survival rate for stroke remains poor, with a high rate of recurrence and disability. Therefore, there is a strong need for new treatments and better diagnostic tools to improve outcomes.

SSTR2, short for sestamyl-尾-2, is a protein that is expressed in the brain and has been shown to play a role in the development and progression of stroke. Studies have shown that SSTR2 is involved in the formation of blood-brain barrier (BBB), which is a barrier that separates the brain from the blood and plays a crucial role in maintaining brain health.

SSTR2 has also been shown to be involved in the regulation of cellular processes that are important for stroke recovery, such as inflammation and neurogenesis. Additionally, SSTR2 has been linked to the development of neurodegeneration, which is a hallmark of stroke.

Because of these findings, SSTR2 has become a promising drug target for stroke. Researchers are investigating the potential benefits and risks of targeting SSTR2 with drugs, with the goal of improving outcomes for stroke patients.

One approach to targeting SSTR2 is through the use of small molecules, which are drugs that can interact with proteins to alter their activity. Researchers have identified a number of small molecules that have been shown to interact with SSTR2 and have the potential to be used as treatments for stroke.

One of the small molecules that has shown promise is N-Acetyl-L-Tyrosine (NAT), which is a neurotransmitter that is involved in the regulation of mood, anxiety, and inflammation. Studies have shown that NAT can interact with SSTR2 and reduce its activity, which may have potential benefits for stroke treatment.

Another small molecule that has potential as a stroke treatment is 2-[(2-methylpropyl)amino]-2-[(2-methylpropyl)amino]-3-[(2-methylpropyl)amino]-6-[(2-methylpropyl)amino]-7-nitro-1-[(2-methylpropyl)amino]-3-[(2-methylpropyl)amino]-2,4-dihydroxybenzotriazole (MPA), which is a drug used to treat migraines. MPA has been shown to interact with SSTR2 and reduce its activity, which may have potential benefits for stroke treatment.

While SSTR2 is an attractive drug target for stroke because of its involvement in the development and progression of the disease, it is important to consider the potential risks and side effects of any new treatments. Researchers are working to fully understand the risks and benefits of targeting SSTR2 with drugs, and to develop safe and effective treatments for stroke.

In conclusion, SSTR2 is a protein that is involved in the development and progression of stroke. Studies have shown that SSTR2 is involved in the formation of the blood-brain barrier, regulation of cellular processes important for stroke recovery, and the development of neurodegeneration. As a result, SSTR2 is a promising drug target for stroke. While more research is needed to fully understand the risks and benefits of targeting SSTR2 with drugs, the potential benefits of such treatments are exciting and worth further investigation.

Protein Name: Somatostatin Receptor 2

Functions: Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization

The "SSTR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSTR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets